STOCKS TELEGRAPH

Tag: Sharps Technology Stock

  • Sharps Technology (STSS) Stock Rises After Major Shipments

    Sharps Technology (STSS) Stock Rises After Major Shipments

    Shares of Sharps Technology, Inc. (NASDAQ: STSS) were surging 75.40% to $6.56 as of the last check in recent trading. The momentum followed announcement of its first commercial product shipments under three separate customer orders. These deliveries mark a major transition for STSS from development-focused operations to a revenue-generating commercial enterprise.

    Initial Deliveries of Smart Syringes Begin

    Sharps Technology commenced its inaugural shipment of SoloGard smart safety syringes under a previously announced $50 million, five-year supply agreement with a U.S.-based leader in IV flushing solutions.

    The initial $400,000 order includes customized 10mL SoloGard syringes produced at Sharps Technology’s upgraded manufacturing facility in Hungary. SoloGard syringes feature an FDA- and WHO-approved design with ultra-low waste capability, luer lock compatibility, and single-use safety mechanisms. The order represents STSS’ first revenue-generating delivery under this strategic contract, which may involve up to 500 million units.

    Expansion Across Global Healthcare and Cosmetic Markets

    In a separate transaction, Sharps fulfilled a $100,000 purchase order for its SecureGard syringes to a Hungarian vaccine provider. SecureGard, also FDA- and WHO-approved and CE Mark-certified, includes advanced safety features such as an active recessed safety system and ultra-low waste design.

    Simultaneously, Sharps Technology shipped 200,000 low dead space 1mL syringes to a Swiss-based firm specializing in cosmetic, dental, and ophthalmic injectable therapies. These syringes, intended for use in Botox injection pens, represent the first installment of a 1-million-unit commitment.

    Strategic Manufacturing and Global Market Expansion

    All products were manufactured at Sharps Technology’s newly enhanced Hungary facility, which now features next-generation molding and automation systems. These upgrades allow for high-precision, scalable production to support both current and future purchase obligations.

    Sharps Technology is well-positioned to satisfy the expanding need for cutting-edge safety syringe solutions worldwide by acquiring several foreign clients and moving into active commercial operations. This accomplishment demonstrates STSS’ successful long-term strategic plan execution and its rise to prominence in international healthcare supply chains.

  • Sharps Technology (STSS) Stock Climbs In Pre-Hour Trading After A Supply Deal

    Sharps Technology (STSS) Stock Climbs In Pre-Hour Trading After A Supply Deal

    The stock price of Sharps Technology, Inc. (NASDAQ: STSS) saw a significant increase today, going up 27.20% to $6.36 in the pre-market period. This positive trend comes after the business said that it had received a $400,000 buy order from a significant IV flushing solution supplier in the United States. Being the first order under STSS’ previously revealed $50 million supply arrangement in July 2024, the transaction represents a significant turning point.

    A Turning Point in the Creation of Revenue

    As the business moves from strategic planning to operational execution, the most recent development represents a significant turning point for Sharps Technology. STSS demonstrates its dedication to shareholder value by formally entering its revenue-generating phase with its first order. Sharps Technology’s Hungarian facility is fully equipped and ready to fulfill the order, delivering pump-compatible 10mL SoloGard syringes and recording its first revenue of 2025.

    Execution of Long-Term Supply Contract

    This initial purchase activates the broader five-year agreement, which outlines the supply of approximately 500 million customized SoloGard syringes to the U.S.-based healthcare supplier. It is projected that the transaction will bring in around $50 million, establishing Sharps Technology as a major force in the medical syringe production industry. In order to complete product certifications and effectively scale production in response to anticipated demand, ongoing customer communication is under progress.

    Investing Strategically to Increase Production Efficiency

    To accommodate higher production quantities, Sharps Technology has made targeted investments in sophisticated manufacturing capabilities. Among these initiatives is the integration of automation and high-precision molding systems via collaborations with BBS Automation and Husky Medical Molds powered by Schöttli.

    These technical advancements support STSS’ mission to provide creative and sustainable syringe solutions by increasing operating efficiency and guaranteeing high-quality production. Now that this first order has established the groundwork, Sharps Technology is in a great position to increase operations and fulfill its supply commitments, indicating a promising future for the business and long-term value for investors.